Hoth Therapeutics Inc

HOTH

Company Profile

  • Business description

    Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.

  • Contact

    720 Monroe Street
    Suite E514
    HobokenNJ07030
    USA

    T: +1 866 239-7459

    https://www.hoththerapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    3

Stocks News & Analysis

stocks

Is this the catalyst US tech gian needs?

Muse models may just be the spark that the rirm needed in AI model development.
stocks

ASX share plunges due to Iran related weakness

Despite headwinds our long-term outlook is unchanged.
stocks

Investors punish this ASX player after acquisition

We think the floundering stock price is not reflective of underlying asset value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,112.805.800.06%
CAC 408,259.6013.810.17%
DAX 4023,803.953.04-0.01%
Dow JONES (US)47,916.57269.23-0.56%
FTSE 10010,600.532.95-0.03%
HKSE25,893.54141.140.55%
NASDAQ22,902.8980.480.35%
Nikkei 22556,573.00351.11-0.62%
NZX 50 Index12,988.58192.86-1.46%
S&P 5006,816.897.77-0.11%
S&P/ASX 2008,927.0015.200.17%
SSE Composite Index3,986.220.01-0.00%

Market Movers